Some recent initiatives generating evidence for MRD testing in AML
| Initiative . | Goal . | Membership . |
|---|---|---|
| ELN AML MRD guidelines: European LeukemiaNet | Evidence-based clinical standard of care consensus guidelines for AML MRD testing | International committee of physicians and scientists with expertise in AML MRD |
| MPAACT: Measurable Residual Disease Partnership and Alliance in Acute Myeloid Leukemia Clinical Treatment | Industry-led research alliance advancing efforts to establish MRD as a surrogate endpoint for overall survival in the treatment of AML | Founded in 2018 by Janssen, Genentech, Novartis, and Celgene (now Bristol Myers Squibb), with recent additions of Amgen, AbbVie, and Kronos Bio.40 |
| FNIH: Foundation of the NIH Biomarkers Consortium for AML MRD | Establish and validate new methods for detecting MRD in AML, including a library of reference standards and evidence of clinical utility. | FDA, NIH, 2 academic partners, and 15-25 private sector industry partners |
| Pre-MEASURE | NIH-led retrospective project on >1000 patients to determine the impact of pre-alloHCT MRD testing in CR1 blood using ultradeep NGS | In collaboration with the CIBMTR |
| MEASURE: Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events | Prospective multicenter protocol to determine clinical utility of MRD testing in up to 1000 AML patients undergoing alloHCT (NCT05224661) | National Marrow Donor Program, CIBMTR, NIH, with initially up to 16 US-based high-volume alloHCT centers |
| NCI MyeloMATCH | Upcoming national precision medicine master protocol for AML. Rapid drug efficacy screening using genetic assignments and MRD testing. | National Cancer Institute, ECOG-ACRIN, SWOG, The Alliance, Canadian Cancer Trials Group Children's Oncology Group |
| Initiative . | Goal . | Membership . |
|---|---|---|
| ELN AML MRD guidelines: European LeukemiaNet | Evidence-based clinical standard of care consensus guidelines for AML MRD testing | International committee of physicians and scientists with expertise in AML MRD |
| MPAACT: Measurable Residual Disease Partnership and Alliance in Acute Myeloid Leukemia Clinical Treatment | Industry-led research alliance advancing efforts to establish MRD as a surrogate endpoint for overall survival in the treatment of AML | Founded in 2018 by Janssen, Genentech, Novartis, and Celgene (now Bristol Myers Squibb), with recent additions of Amgen, AbbVie, and Kronos Bio.40 |
| FNIH: Foundation of the NIH Biomarkers Consortium for AML MRD | Establish and validate new methods for detecting MRD in AML, including a library of reference standards and evidence of clinical utility. | FDA, NIH, 2 academic partners, and 15-25 private sector industry partners |
| Pre-MEASURE | NIH-led retrospective project on >1000 patients to determine the impact of pre-alloHCT MRD testing in CR1 blood using ultradeep NGS | In collaboration with the CIBMTR |
| MEASURE: Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events | Prospective multicenter protocol to determine clinical utility of MRD testing in up to 1000 AML patients undergoing alloHCT (NCT05224661) | National Marrow Donor Program, CIBMTR, NIH, with initially up to 16 US-based high-volume alloHCT centers |
| NCI MyeloMATCH | Upcoming national precision medicine master protocol for AML. Rapid drug efficacy screening using genetic assignments and MRD testing. | National Cancer Institute, ECOG-ACRIN, SWOG, The Alliance, Canadian Cancer Trials Group Children's Oncology Group |